# A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies

> **NCT07347171** · PHASE1 · RECRUITING · sponsor: **Cullgen (Shanghai),Inc** · enrollment: 45 (estimated)

## Conditions studied

- Leukemia
- AML
- MDS
- AML (Acute Myelogenous Leukemia)
- MDS (Myelodysplastic Syndrome)

## Interventions

- **DRUG:** CG009301 for Injection

## Key facts

- **NCT ID:** NCT07347171
- **Lead sponsor:** Cullgen (Shanghai),Inc
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-17
- **Primary completion:** 2027-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07347171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07347171, "A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07347171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*